Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth investment with 2023 CAPEX at 25% of sales Solid free cash flow at CHF 329 million Proposed 14% dividend increase from CHF 3.50 to CHF 4.00 per share Return of excess […]
continue readingLonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023. The bonds have a maturity of 4.5 years and 7.5 years respectively with coupons of 2.250% and 2.600%. The issuer is […]
continue readingCapital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023: higher end of mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin Business growth in 2024 will be offset by one-off events, with an […]
continue readingVaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
. New agreement to establish global commercial manufacturing capacity for Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration builds on Vaxcyte’s current strategy to conduct initial commercial launch of VAX-24 in adults from existing Lonza facilities in Visp (CH) Long-standing relationship between the companies further enhanced as Vaxcyte progresses lead vaccine […]
continue readingLonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza’s end-to-end integrated offering for manufacturing antibody-drug conjugates (ADCs) drug substance and drug product Approximately 115 new jobs anticipated at Lonza Stein (CH), with operations starting in 2027 Lonza, […]
continue readingLonza Further Extends Collaboration with Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation Two new purpose-built large-scale bioconjugation suites in Lonza’s Ibex® Dedicate Biopark to generate around 180 new […]
continue readingLonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an overview of Lonza’s offerings, capabilities, markets and sources of competitive advantage Lonza reconfirms Outlook 2023 at mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin Lonza today announced its plans for the company’s […]
continue readingBoard Announcement
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17 confirmed Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on […]
continue readingLonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a margin of 30% Good momentum in commercial CDMO business Group Outlook 2023 update: mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin, reflecting […]
continue readingLonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate […]
continue reading